Microbiology and drug resistance mechanisms of fully resistant pathogens

Current Opinion in Microbiology

Volumn 7, Issue 5, 2004, Pages 439-444

  Walsh, Fiona M ^a   Amyes, Sebastian G B ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENE PRODUCT; GLYCOPEPTIDE; IMIPENEM; KETOLIDE; LACTIC ACID; LINEZOLID; MACROLIDE; PEPTIDOGLYCAN; PORIN; QUINOLONE DERIVATIVE; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; TELITHROMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIOPHAGE TYPING; BACTERIUM ISOLATION; COMMENSALISM; DRUG MISUSE; DRUG TOLERANCE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL TRACT; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HYDROLYSIS; INTENSIVE CARE UNIT; LIFESTYLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPERON; PATHOGENICITY; PENICILLIN RESISTANCE; PHENOTYPE; PNEUMONIA; PREVALENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PSEUDOMONAS AERUGINOSA; REPLICON; REVIEW; STAPHYLOCOCCUS AUREUS; TRANSPOSON; TREATMENT FAILURE; UNITED STATES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; INSERTION SEQUENCES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; TRANSPOSONS;

EID: 4644363284     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2004.08.007     Document Type: Review

References (42)

1. S.G.B. Amyes, and C.J. Thomson Antibiotic resistance in the ICU; the eve of destruction Brit J Inten Care 5 1995 263 271
2. R. Leclercq, E. Derlot, J. Duval, and P. Courvalin Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium N Engl J Med 319 1988 157 161
3. M. Arthur, C. Molinas, F. Depardieu, and P. Courvalin Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecalis BM4147 J Bacteriol 175 1993 117 127
4. M. Arthur, and P. Courvalin Genetics and mechanisms of glycopeptide resistance in enterococci Antimicrob Agents Chemother 37 1993 1563 1571
5. R. Quintiliani, S. Evers, and P. Courvalin The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci J Infect Dis 167 1993 1220 1223
6. M. Fines, B. Perichon, P. Reynolds, D.F. Sahm, and P. Courvalin VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405 Antimicrob Agents Chemother 43 1999 2161 2164
7. H. Goossens The epidemiology of vancomycin-resistant enterococci Curr Opin Infect Dis 12 1999 537 541
8. A.R. Brown, A.C. Townsley, and S.G.B. Amyes Diversity of Tn1546 elements in clinical isolates of glycopeptide-resistant enterococci from Scottish hospitals Antimicrob Agents Chemother 45 2001 1309 1311 This paper demonstrates that the diversity of the vanA operon was dependent on the health region that the patient was treated in.
9. Comptroller and Auditor General: Improving patient care by reducing the risk of hospital acquired infection: a progress report. 2004. National Audit Office, London.
10. P.C.L. Moore, and J.A. Lindsay Molecular characterisation of the dominant UK methicillin-resistant Staphylococcus aureus strains, EMRSA-15 and EMRSA-16 J Med Microbiol 51 2002 516 521
11. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135 146
12. K. Hiramatsu, N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 1670 1673
13. K. Hanaki, H KuwaharaArai, S. BoyleVavra, R.S. Daum, H. Labischinski, and K. Hiramatsu Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 J Antimicrob Chemother 42 1998 199 209
14. W.C. Noble, Z. Virani, and R.G.A. Cree Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus FEMS Microbiol Lett 72 1992 195 198
15. D.M. Sievert, M.L. Boulton, G. Stoltman, D. Johnson, M.G. Stobierski, F.P. Downes, P.A. Somsel, J.T. Rudrik, W. Brown, and W. Hafeez Staphylococcus aureus resistant to vancomycin Morbidity and Mortality Weekly Report 51 2002 565 567 This report alerted the world to the fact that high-level vancomycin resistance was now a reality in multi-resistant Staphylococcus aureus.
16. F.C. Tenover, L.M. Weigel, P.C. Appelbaum, L.K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C.M. O'Hara, and L. Jevitt Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania Antimicrob Agents Chemother 48 2004 275 280 This paper outlines the detail of the latest spread of the vanA operon into multi-resistant Staphylococcus aureus.
17. M. Quirk First VRSA isolate identified in USA Lancet Infect Dis 2 2002 510
18. J.Y. Fagon, J. Chastre, Y. Domart, J.L. Trouillet, J. Pierre, C. Darne, and C. Gibert Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques Am Rev Respir Dis 139 1989 877 884
19. K. Senda, Y. Arakawa, K. Nakashima, H. Ito, S. Ichiyama, K. Shimokata, N. Kato, and M. Ohta Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems Antimicrob Agents Chemother 40 1996 349 353
20. D.M. Livermore, and N. Woodford Carbapenemases: a problem in waiting? Curr Opin Microbiol 3 2000 489 495
21. R.H. Paton, R.S. Miles, J. Hood, and S.G.B. Amyes ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii Int J Antimicrob Agents 2 1993 81 88
22. W. Scaife, H.-K. Young, R.H. Paton, and S.G.B. Amyes Transferable imipenem-resistance in Acinetobacter species from a clinical source J Antimicrob Chemother 36 1995 585 586
23. H.M. Donald, W. Scaife, S.G.B. Amyes, and H.K. Young Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92 Antimicrob Agents Chemother 44 2000 196 199 This paper showed that carbapenem resistance in Acinetobacter came from a novel and completely unexpected group of class D beta-lactamases.
24. L.M. Dalla-Costa, J.M. Coelho, H.A.P.H. Souza, M.E.S. Castro, C.J.N. Stier, K.L. Bragagnolo, A. Rea-Neto, S.R. Penteado, D.M. Livermore, and N. Woodford Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil J Clin Microbiol 41 2003 3403 3406
25. M. Afzal-Shah, N. Woodford, and D.M. Livermore Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii Antimicrob Agents Chemother 45 2001 583 588 This paper demonstrated that there was more than one cluster of class D beta-lactamases responsible for carbapenem resistance in Acinetobacter baumannii.
26. D.M. Livermore The threat from the pink corner Ann Med 35 2003 226 234
27. D.J. Farrell, I. Morrissey, S. Bakker, and D. Felmingham Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study J Antimicrob Chemother 50 2002 39 47
28. O. Dobay, F. Rozgonyi, E. Hajdu, E. Nagy, M. Knausz, and S.G.B. Amyes Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary J Antimicrob Chemother 51 2003 887 893
29. M. Monaco, R. Camilli, F. D'Ambrosio, M. Del Grosso, and A. Pantosti Evolution of macrolide resistance in Streptococcus pneumoniae [abstract] Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases 2004 p1139
30. M. Rantala, P. Houvinen, and J. Jalava Finnish Study Group for Antimicrobial Resistance: Macrolide resistance and its genetic mechanism in Streptococcus pneumoniae in Finland 2002, with special reference to telithromycin resistance [abstract] Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases 2004 p1475
31. K.P. Heilmann, S. Beekmann, S.S. Richter, J. Garcia-de Lovias, and G. Doern Antimicrobial resistance with Streptococcus pneumoniae in 2003 - results of the multinational GRASP surveillance program [abstract] Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases 2004 p1130
32. D. Farrell, and I. Morrissey Distribution of macrolide resistance mechanisms in Streptococcus pneumoniae; 3 year update from the PROTECT study [abstract] Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases 2004 p1148
33. T.A. Davies, B.E. Dewasse, and P.C. Appelbaum In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae Antimicrob Agents Chemother 44 2000 414 417
34. F. Walsh, J. Willcock, and S.G.B. Amyes High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae J Antimicrob Chemother 52 2003 345 353
35. L. McGee, L. McDougal, J. Zhou, B.G. Spratt, F.C. Tenover, R. George, R. Hakenbeck, W. Hryniewicz, J.C. Lefevre, A. Tomasz, and K.P. Klugman Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network J Clin Microbiol 39 2001 2565 2571
36. M.P. Montanari, I. Cochetti, M. Mingoia, and P.E. Varaldo Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae Antimicrob Agents Chemother 47 2003 2236 2241
37. A. Tait-Kamradt, T. Davies, P.C. Appelbaum, F. Depardieu, P. Courvalin, J. Petitpas, L. Wondrack, A. Walker, M.R. Jacobs, and J. Sutcliffe Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America Antimicrob Agents Chemother 44 2000 3395 3401
38. M. Del Grosso, F. Iannelli, C. Messina, M. Santagati, N. Petrosillo, S. Stefani, G. Pozzi, and A. Pantosti Macrolide efflux genes mefA and mefE are carried by different genetic elements in Streptococcus pneumoniae J Clin Microbiol 40 2002 774 778
39. G.A. Syrogiannopoulos, I.N. Grivea, A. Tait-Kamradt, G.D. Katopodis, N.G. Beratis, J. Sutcliffe, P.C. Appelbaum, and T.A. Davies Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece Antimicrob Agents Chemother 45 2001 342 344
40. L. McGee, K.P. Klugman, A. Wasas, T. Capper, and A. Brink Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants [erm(B) and mef(A)] in South Africa Antimicrob Agents Chemother 45 2001 1595 1598
41. R. Novak, B. Henriques, E. Charpentier, S. Normark, and E. Tuomanen Emergence of vancomycin tolerance in Streptococcus pneumoniae Nature 399 1999 590 593
42. J.A. McCullers, B.K. English, and R. Novak Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis J Infect Dis 181 2000 369 373